Open Access Rheumatology-Research and Reviews, published by DOVE MEDICAL PRESS LTD, is a distinguished journal that has been a vital part of the rheumatology field since its inception in 2009. With an ISSN of 1179-156X, this journal is dedicated to disseminating groundbreaking research and comprehensive reviews in the discipline of rheumatology, making it an essential resource for researchers, clinicians, and students alike. It boasts an impressive Q3 ranking in the Rheumatology category for 2023, reflecting its relevance and quality within a highly competitive landscape, where it ranks in the 51st percentile among its peers as indicated by the Scopus Ranks. As an open-access platform, it ensures that critical findings and insights are easily accessible to a global audience, promoting collaboration and knowledge sharing. The journal's scope includes a wide range of topics within rheumatology, aimed at advancing understanding and treatment of musculoskeletal disorders and autoimmune diseases. Its headquarters is located in New Zealand, positioning it as a key player in the international research community.

Gastrointestinal Disorders is a prominent open-access journal published by MDPI, based in Switzerland, that focuses on the latest research and innovations in the fields of gastroenterology, hepatology, and immunology. Since its inception in 2019, the journal has provided a vital platform for researchers and professionals to disseminate their findings, engaging with a global audience keen on advancing knowledge in gastrointestinal health. With a dedicated commitment to high-quality, peer-reviewed articles, Gastrointestinal Disorders has gained recognition in 2023, achieving Q3 status in gastroenterology and notable rankings in several other categories, including a respectable position in the quartiles for hepatology, immunology, and oncology. Despite its recent establishment, the journal has quickly become a valuable resource, facilitating open access to critical insights in the study of gastrointestinal diseases and their management, ensuring that emerging research is readily available to inform clinical practice and educate future professionals.

ANNALS OF THE RHEUMATIC DISEASES, published by BMJ Publishing Group, stands as a leading academic journal in the realm of rheumatology and related fields, including biochemistry, immunology, and genetics. With an esteemed impact factor and a consistent ranking in the upper echelons of its category (Q1) as per the latest evaluations, this journal represents the forefront of research and innovation, fostering scientific advancement from 1945 to the present. As the top journal in the Medicine - Rheumatology category and achieving remarkable percentiles in various interdisciplinary categories, it serves as a critical platform for researchers, clinicians, and students dedicated to understanding and addressing rheumatic diseases. Although it does not currently offer open access, its rigorous peer-review process ensures the dissemination of high-quality research findings that are paramount in enhancing clinical practices and advancing scientific discourse. Readers can expect to be challenged and inspired by the breadth of studies and reviews that address the complexities of rheumatology and its intersecting scientific domains.

Current Treatment Options in Rheumatology, published by SPRINGERNATURE, is a pivotal journal focused on advancing the field of rheumatology through the dissemination of cutting-edge research and comprehensive reviews. With an emphasis on current therapeutic strategies, this journal aims to provide healthcare professionals, researchers, and students with up-to-date information on the latest treatment modalities for rheumatic diseases. Although it operates under a subscription model, it offers a platform for sharing significant findings that can influence clinical practice and policy within the field of rheumatology. By promoting insightful discussions and collaborations, Current Treatment Options in Rheumatology plays a crucial role in shaping the future of rheumatic disease management and improving patient outcomes.

The Egyptian Rheumatologist is a peer-reviewed Open Access journal dedicated to advancing the field of rheumatology. Published by Elsevier since 2011, the journal aims to disseminate high-quality research, clinical innovations, and reviews that cover a wide range of topics related to autoimmune diseases, arthritis, and musculoskeletal disorders. With an ISSN of 1110-1164 and an E-ISSN of 2090-2433, it has achieved a respectable rank of #50 out of 73 in the medicine/rheumatology category according to Scopus, positioning it in the 32nd percentile among its peers. Operating from its base in Amsterdam, Netherlands, the journal provides an accessible platform for researchers, professionals, and students, encouraging a collaborative exchange of cutting-edge knowledge that is essential for the ongoing developments in rheumatologic care and research. The Open Access model ensures that critical findings and advancements are available to a global audience, fostering further research and education within this vital field.

CLINICAL AND EXPERIMENTAL ALLERGY is a premier peer-reviewed journal dedicated to advancing the scientific understanding of allergy and immunology. Published by Wiley in the United Kingdom, this esteemed journal maintains a significant impact factor, reflecting its high standards and influential research contributions. With an impressive history since its inception in 1971, the journal is poised to continue leading the discourse in the field until at least 2024. It is ranked in the Q2 quartile for both Immunology and Allergy categories, further highlighting its reputable standing within the academic community. The journal's Scopus rankings showcase its academic relevance, securing the 49th and 51st positions in the Medicine and Immunology categories, respectively. Researchers, professionals, and students will find vital insights and contemporary research trends within its pages, making it an essential resource for those invested in understanding and addressing allergic diseases and disorders.

ALLERGY AND ASTHMA PROCEEDINGS, published by Ocean Side Publications Inc, is a vital resource in the fields of Immunology, Allergy, and Pulmonary Medicine. With an impressive trajectory of publication from 1996 to 2024, this journal serves as a platform for cutting-edge research and advancements in the understanding of allergic and asthmatic conditions. Positioned in the Q3 quartile for Immunology and Allergy and Q2 for both Medicine (miscellaneous) and Pulmonary Medicine, the journal exhibits a robust impact within the academic community, boasting Scopus rankings that reflect its significance. The journal offers open access options, allowing for the dissemination of critical findings to a wider audience. Aimed at researchers, healthcare professionals, and students alike, ALLERGY AND ASTHMA PROCEEDINGS addresses the complexities of respiratory diseases and facilitates the sharing of knowledge that is essential to improving patient care and outcomes.

JOURNAL OF RHEUMATOLOGY, published by the J Rheumatol Publ Co, stands as a distinguished platform within the fields of rheumatology and immunology since its inception in 1974. With an impressive impact evidenced by its 2023 rankings—Q1 in Rheumatology and Q2 in both Immunology and Allergy—the journal has secured its position as a vital resource for researchers and practitioners alike. The journal is dedicated to advancing clinical and experimental knowledge in the pathogenesis, diagnosis, and management of rheumatic diseases, providing a rich repository of peer-reviewed articles that drive innovation in treatment protocols and patient care. Although it operates under a subscription model, the journal remains accessible to a broad audience committed to advancing their understanding of these critical areas. Located in Toronto, Canada, it continues to attract contributions from leading experts globally, making it an essential read for anyone keen on staying at the forefront of rheumatological research and practice.

Pediatric Rheumatology is a leading peer-reviewed open access journal published by BMC, dedicated to disseminating high-quality research in the field of pediatric rheumatology. Since its inception in 2007, the journal has established itself as a vital resource for healthcare professionals, researchers, and students focused on pediatric immunology, rheumatology, and child health, maintaining an impressive Q1 ranking in Pediatrics and Q2 in Immunology and Allergy as well as Rheumatology for 2023. It is recognized for its impact on advancing knowledge and clinical practice, with significant contributions noted in various studies and case reports. With access options that embrace the ethos of open science, all articles published in Pediatric Rheumatology are freely available, promoting collaborative research and discussion among practitioners across the globe. The journal welcomes submissions that encapsulate innovative research, clinical trials, and reviews that address both current challenges and advancements within the pediatric rheumatology landscape.

RHEUMATOLOGY, published by Oxford University Press, is a leading journal in the fields of Pharmacology and Rheumatology, recognized for its significant contribution to advancing the understanding and treatment of rheumatic diseases. With an impressive impact factor and ranking within the top quartiles for both medical pharmacology and rheumatology, this journal serves as an essential resource for researchers, clinicians, and healthcare professionals. The journal spans an extensive publication history, with contributions from 1952 to 1995 and from 1998 to 2024, reflecting its enduring commitment to disseminating high-quality research. The Open Access option allows for broader dissemination of knowledge, enhancing the visibility of groundbreaking studies. Positioned in the United Kingdom, RHEUMATOLOGY not only offers valuable insights into the latest therapeutic advancements and clinical guidelines but also fosters collaboration across disciplines, ensuring that practitioners stay at the forefront of innovation in the management of rheumatic conditions.